The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing
This article was originally published in Pharmaceutical Approvals Monthly
After two failed studies, The Medicines Co.’s rapid-acting I.V. antiplatelet drug reduces events by more than 20% in the Phase III CHAMPION PHOENIX angioplasty trial against Plavix. However, the company is already facing demand for studies against the newer and more potent antiplatelet drugs Brilinta and Effient.
You may also be interested in...
The Medicines Co.’s transition away from near-total reliance on Angiomax seems ever closer to reality, given its full pipeline and intensive business development activities. The new products stretch beyond the hospital catheterization lab, as the company builds franchises in hospital anti-infectives, pain management, and hemostatis.
TMC reported successful top-line data from its Phase III PHOENIX study of its anticlotting drug cangrelor and expects to file an NDA this year.
Speeding heart attack patients into the PCI lab may have blurred the timeline on their MIs and botched endpoint data, says Meanwell.